Ascendis Pharma Reports Strong Q2 2025 Results and Advances Key Therapies

The latest update is out from Ascendis Pharma ( (ASND) ).

Ascendis Pharma announced its financial results for the second quarter of 2025, reporting a significant revenue increase to €158.0 million, driven by strong sales of YORVIPATH® and SKYTROFA®. The company is advancing its pipeline with the FDA’s priority review of TransCon CNP for treating achondroplasia, and the recent approval of SKYTROFA® for adult growth hormone deficiency. These developments are expected to enhance Ascendis Pharma’s market position and financial profile as it continues to address unmet medical needs in rare endocrine diseases.

The most recent analyst rating on (ASND) stock is a Buy with a $165.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.

Spark’s Take on ASND Stock

According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.

Ascendis Pharma’s stock score is primarily impacted by its weak financial performance and technical analysis, indicating financial instability and bearish market trends. While the earnings call provides some positive developments, the company faces significant profitability challenges and market uncertainties.

To see Spark’s full report on ASND stock, click here.

More about Ascendis Pharma

Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, focusing on developing innovative therapies in the field of endocrinology and oncology. The company is known for its TransCon technology, which is used to create long-acting prodrugs, and its primary products include YORVIPATH® and SKYTROFA®, targeting endocrine rare diseases and growth hormone deficiencies.

Average Trading Volume: 437,039

Technical Sentiment Signal: Buy

Current Market Cap: $11.27B

For detailed information about ASND stock, go to TipRanks’ Stock Analysis page.